They also helped to identify genes particularly sensitive to reduced CBP KAT activity that could be used as biomarkers in pathologies in which this protein has been involved, such as Huntington's disease, Alzheimer's disease and aging-related cognitive decline (Valor et al., 2013a; Achour et al., 2015; Chatterjee et al., 2018; Hervás-Corpión et al., 2018). Here, CREBBP is linked to early-onset autosomal dominant Alzheimer disease.